- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00213005
Safety and Acceptability of Carraguard® in HIV Positive Women and Men
A Phase 1 Safety and Acceptability Study of Carraguard® Among HIV Positive Women and Men in Durban, South Africa
Přehled studie
Detailní popis
We proposed a safety study of the Council's lead candidate microbicide, Carraguard® in three cohorts in Durban, South Africa: sexually abstinent HIV-positive women, sexually abstinent HIV-positive men, and sexually active HIV-positive women. Sexually active women must be in an HIV-positive seroconcordant relationship (confirmed by HIV testing of the woman and her male partner) and written informed consent was obtained from the male partners. Women and men in each cohort were randomized to one of three study groups: Carraguard® gel, its matching placebo methyl-cellulose gel, or no product.
The main objectives of this study were to investigate changes in the vulvar, vaginal, and cervical epithelia, the vaginal flora, and HIV-1 shedding in the genital tract of female participants, and changes of the penile skin and epithelia of male participants. We also evaluated symptoms reported by participants, and several dimensions of the acceptability of and compliance with the study or placebo gel. Reactions to a non-contraceptive microbicide were assessed, as well as reasons for voluntary discontinuation and non-use of Carraguard® or the placebo (determined by review of daily diary) was recorded. Exit focus group discussions were held with male and female participants to discuss aspects of acceptability and compliance. Self-reported symptoms were also investigated by clinical examination as needed and study endpoints included genital itching or burning, frequent urination, burning while urinating, genital pain, pain during sex, and abnormal vaginal or penile discharge.
Typ studie
Zápis
Fáze
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
-
Durban, Jižní Afrika
- Medical Research Council
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Positive for HIV-1 by licensed HIV test (with confirmation) and agree to be informed of the test result
- Age 18 to 45 years old, for women (no maximum age for men)
- In good health, defined as CD4+ cell count >200 x 106/L and current absence of opportunistic infections that may interfere with protocol adherence
- If on treatment for HIV infection (including immune-boosters such as Moducare and vitamins): treatment should stay constant for the duration of the study
- For sexually abstinent cohort: Willing to abstain from sexual intercourse and masturbation for the duration of the study (3 weeks) and for the 48 hours before joining the study
- For sexually active cohort: Willing to have sex with only one male partner, and male partner is willing to have sex with only the participant, for the duration of the study
- Regular menstrual cycle (3-5 weeks between periods) or amenorrheic due to long-term (three months or more) DMPA use (and have had no DMPA-related side effects that could interfere with study participation in the last 6 months)
- Planning on living in Durban for the next 6 months
- Willing to refrain from using any other vaginal products for the duration of the study (3 weeks), including other spermicides, diaphragm/cervical cap, traditional drying and tightening agents, douches, tampons, and medicinal products
- Willing and able to comply with all other aspects of the study protocol, including clinical evaluations and study gel administration (if applicable)
- Willing and able to give informed consent.
Exclusion Criteria:
- Currently pregnant, menopausal or lactating, or desire to become pregnant at the time of study participation
- Current or recent participation (within past 30 days) in any other clinical trial, including trials of HIV therapeutics and trials of vaginal products (this does not include the ongoing study in the Department of Paediatrics of King Edward VIII Hospital)
- Delivery, miscarriage or abortion within the last six weeks
- Gynecological surgery or instrumentation in the last three months
- History of non-menstrual vaginal bleeding with intercourse in the last month
- Presence of a clinically detectable genital abnormality (i.e. vulvar, vaginal, cervical and/or perianal ulcer and/or lesion) on which the epithelium is currently disrupted or is likely to disrupt (e.g. herpes blister). Women with healed/dried-up lesions from a past infection, or with a lesion on which the epithelium is currently intact or unlikely to disrupt, will be eligible for enrollment.
- Presence of a sexually transmitted infection (STI), symptomatic yeast infection, or bacterial vaginosis (BV), as diagnosed by clinical exam or laboratory testing at screening. Women with asymptomatic yeast infection or BV may be enrolled.
- Abnormal Pap smear (CIN I or higher) at screening
- Use of any spermicide or spermicidally lubricated condom within the week prior to enrollment.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Diagnostický
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
---|
Safety: genital findings, epithelial disruption, vaginal flora changes, genital shedding, inflammation & self-reported symptoms. Assessments were made weekly at days 7, 14 & 21.
|
Acceptability: interviewer-administered questionnaires & daily diaries. Interviewer-administered questionnaires assessed at day 21 & daily diaries were assessed at days 14 and 21.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Janneke van de Wijgert, Ph.D., International Antiviral Therapy Evaluation Center
- Vrchní vyšetřovatel: Gita Ramjee, Ph.D, Medical Research Council
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- Population Council #297
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na HIV infekce
-
Ottawa Hospital Research InstitutePfizerDokončenoHIV infekce | HIV-1 infekce | Mycobacterium Avium Complex (MAC)Kanada
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...AbbottDokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-IntracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
PfizerDokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
PfizerDokončenoHIV infekce | Infekce Mycobacterium Avium-IntracellulareSpojené státy
-
PfizerDokončenoHIV infekce | Infekce Mycobacterium Avium-Intracellulare | Tuberkulóza, infekce MycobacteriumSpojené státy
Klinické studie na Carraguard (PC-515)
-
Population CouncilCenters for Disease Control and Prevention; Ministry of Health, Thailand; National... a další spolupracovníciDokončeno
-
Population CouncilNational Institute of Allergy and Infectious Diseases (NIAID); United States... a další spolupracovníciDokončenoHIV infekce | Syfilis | Trichomonas vaginitida | Chlamydia trachomatis | Neisseria GonorrhoeaeJižní Afrika
-
Population CouncilUnited States Agency for International Development (USAID); Bill and Melinda...DokončenoHIV infekce | Pohlavně přenosné nemoci | AIDS | Sérokonverze HIVJižní Afrika
-
Population CouncilBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; Ministry of Health, Thailand a další spolupracovníciDokončenoHIV infekce | Herpes Simplex | Syfilis | Trichomonas vaginitida | Chlamydia trachomatis | Neisseria GonorrhoeaeThajsko
-
Population CouncilBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; Ministry of Health, Thailand a další spolupracovníciDokončenoHIV infekce | Syfilis | Trichomonas vaginitida | Chlamydia trachomatis | Nesseria GonorrheaThajsko
-
TretheraNáborOnkologie | Solidní nádor, dospělýSpojené státy
-
University Hospital, Basel, SwitzerlandDokončenoSrdeční selhání; S dekompenzacíŠvýcarsko
-
Boehringer IngelheimDokončeno
-
University of MiamiDočasně nedostupnéPseudoaneuryzma, karotida | PseudoaneuryzmaSpojené státy
-
Children's Hospital of PhiladelphiaIlera HealthcareUkončenoEpilepsie | Roztroušená skleróza | Glaukom | Rakovina | Parkinsonova choroba | HIV/AIDS | ALS | Poruchou autistického spektra | Srpkovitá anémie | Spasticita, svaly | Huntingtonova nemoc | Užívání opioidů | Neuropatie | Smrtelná choroba | Zánětlivé onemocnění střev (IBD) | Neovladatelná bolest | Ptsd | Dyskinetický syndromSpojené státy